P
IONS icon

&Partners’s Ionis Pharmaceuticals IONS Stock Holding History

&Partners’s Portfolio IONS Stock Details IONS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$807K Sell
10,184
-725
-7% -$54.6K ﹤0.01% 1547
2026
Q1 		$819K Buy
10,909
+1,186
+12% +$93.6K ﹤0.01% 1411
2025
Q4 		$769K Sell
9,723
-2,940
-23% -$221K ﹤0.01% 1372
2025
Q3 		$828K Buy
12,663
+905
+8% +$44.2K 0.01% 1177
2025
Q2 		$465K Buy
11,758
+754
+7% +$24.7K ﹤0.01% 1396
2025
Q1 		$343K Buy
11,004
+687
+7% +$22.5K ﹤0.01% 1338
2024
Q4 		$359K Buy
10,317
+711
+7% +$26.6K ﹤0.01% 1239
2024
Q3 		$385K Buy
+9,606
New +$447K 0.01% 987

Other funds holding IONS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

&Partners's IONS Position: Q2 2026 in Review

&Partners reduced its Ionis Pharmaceuticals (IONS) stake by 6.6% in Q2 2026, selling an estimated $54.6K and leaving 10,184 shares worth $807K. The position accounts for ﹤0.01% of the portfolio, ranked #1547.

&Partners first reported a position in IONS in Q3 2024 and has held it in 8 quarters since. The position peaked at $828K in Q3 2025. 514 funds tracked by Wall St. Rank hold IONS as of Q2 2026.

  • &Partners held 10,184 shares of Ionis Pharmaceuticals worth $807K as of Q2 2026.
  • &Partners sold 725 Ionis Pharmaceuticals shares in Q2 2026, an estimated $54.6K.
  • Ionis Pharmaceuticals made up ﹤0.01% of &Partners's portfolio in Q2 2026, its #1547 holding.
  • &Partners first reported a position in Ionis Pharmaceuticals in Q3 2024 and has held it in 8 quarters since.
  • &Partners's Ionis Pharmaceuticals position peaked at $828K in Q3 2025.
  • 514 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q2 2026.

Based on &Partners's 13F filing for Q2 2026, filed 14 Aug 2026.